EFFICACY AND SAFETY OF VALOCTOCOGENE ROXAPARVOVEC 4 YEARS AFTER GENE TRANSFER IN GENER8-1
MC Ozeloa, AD Leavittb, J Mahlanguc, G Kenetd, SW Pipee, S Chouf, R Klamrothg,h, F Peyvandii,j, T Robinsonk, GT Groupl
a Centro de Hematologia e Hemoterapia (Hemocentro), Department of Internal Medicine Faculdade de Ciências Médicas (FCM), Universidade Estadual de Campinas (UNICAMP), Campinas, SP, Brazil
b Adult Hemophilia Treatment Center, University of California San Francisco, San Francisco, CA, USA
c Hemophilia Comprehensive Care Center, Charlotte Maxeke Johannesburg Academic Hospital, University of the Witwatersrand and NHLS, Johannesburg, South Africa
d The National Hemophilia Center and Amalia Biron Research Institute of Thrombosis and Hemostasis, Sheba Medical Center, Tel Hashomer, Tel Aviv University, Tel Aviv, Israel
e Departments of Pediatrics and Pathology, University of Michigan, Ann Arbor, MI, USA
f Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
g Vascular Medicine and Haemostaseology, Vivantes Klinikum im Friedrichshain, Berlin, Germany
h Institute of Experimental Hematology and Transfusion Medicine, University Hospital Bonn, Medical Faculty, University of Bonn, Bonn, Germany
i Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Fondazione Luigi Villa, Milan, Italy
j Università degli Studi di Milano, Department of Pathophysiology and Transplantation, Milan, Italy
k BioMarin Pharmaceutical Inc., Novato, CA, USA
l GENEr8-1 Trial Group
Ver másLido
475
Vezesque se leu este artigo
151
Total PDF
324
Total HTML
| Ano/Mês | Html | Total | |
|---|---|---|---|
| 2025 6 | 13 | 12 | 25 |
| 2025 5 | 68 | 10 | 78 |
| 2025 4 | 42 | 13 | 55 |
| 2025 3 | 53 | 14 | 67 |
| 2025 2 | 33 | 15 | 48 |
| 2025 1 | 27 | 18 | 45 |
| 2024 12 | 25 | 12 | 37 |
| 2024 11 | 36 | 40 | 76 |
| 2024 10 | 27 | 17 | 44 |
